Citations

Clear

9383 citation(s) found for "Thomas, PS".

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial
Basu, A. , Umashankar, Saumya, Melisko, Michelle, Roy, Ritu , Yau, C, Pusztai, L., Chien, A. Jo, Liu, Minetta, Soliman, Hatem, Isaacs, Claudine, Shatsky, Rebecca, Stringer-Reasor, E, Robinson, PA, Kalinsky, Kevin, Thomas, Alexandra, Musthafa, Mina, Asare, Adam, DeMichele, Angela, Veer, Laura van't, Yee, Douglas, Hylton, NM, Olshen, Adam B. , Perlmutter, Jane , Cohen, Ronald , Quandt, Zoe , Esserman, Laura, Rugo, Hope, Nanda, Rita, Umashankar, Saumya , Melisko, Michelle, Yau, Christina , Pusztai, Lajos , Han, Hyo S , Soliman, Hatem, Isaacs, Claudine , Shatsky, Rebecca , Stringer-Reasor, Erica , Yeung, Kay T. , Kalinsky, Kevin M. , Philip, Errol James , Hirst, Gillian L. , DeMichele, Angela , Veer, Laura J. van’t , Yee, Douglas , Hershman, Dawn L.

Mayo Clinic

No container title available | February 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8689063/v1 | PMID 41727611 Get It

Abstract Background Immune checkpoint inhibitors can result in serious, long-lasting immune-related adverse events (irAEs). Early identification of symptoms predictive of irAEs could enhance monitoring and timely intervention. This study assessed whether symptoms within the first 8 weeks of treatment could predict subsequent development of immune-related adrenal insufficiency(AI) or hypothyroidism. Methods This retrospective cohort study analyzed prospectively collected data from the I-SPY2 trial, a phase 2 platform trial for high-risk stage II/III breast cancer across 30 U.S. sites. The cohort included 482 women treated with experimental immunotherapy agents concurrent with weekly paclitaxel neoadjuvant chemotherapy. The primary outcomes were grade ≥ 1 hypothyroidism or AI, adjudicated by an independent safety group, up to 1-year post-treatment. Symptoms and irAEs were assessed using the Common Terminology Criteria for Adverse Events. Symptom burden was quantified as area under the curve (AUC) based on symptom grade and duration. Predictive modeling was performed using logistic regression and ROC analysis; symptom enrichment between cases and controls was evaluated using Fisher’s exact tests. Results Among 482 participants, 107 (22.2%) developed irAEs, with hypothyroidism (n = 61, 12.7%) occurring more frequently than AI (n = 38, 7.9%) at medians of 99 and 105 days from treatment initiation, respectively. Symptom enrichment analysis identified early predictive symptoms. Fatigue (17.2% vs 6.8%, p = 0.011) and rash (20.7% vs 7.8%, p = 0.0037) were predictive of hypothyroidism, while diarrhea (45.9% vs 31%, p = 0.048), constipation (5.4% vs 0.2%, p = 0.018), and taste changes (5.4% vs 0.5%, p = 0.034) were associated with AI. A predictive model demonstrated moderate performance (AUC 0.65 for AI, p < 0.0001; AUC 0.61 for hypothyroidism, p = 0.012). Model accuracy in an external validation cohort was 72.8% for AI and 74.7% for hypothyroidism. Conclusions This study presents a predictive framework to identify patients at risk for adrenal insufficiency and hypothyroidism as irAEs, enabling personalized care and proactive intervention to improve treatment outcomes and safety.
A Proteoform-Resolved Atlas of Human Cardiac Histones
Gao, Zhan, Clemmer, Isabella R., Chan, Hsin-Ju, Osei, Kwame, Weir, Thomas S., Fischer, Matthew S. , Gearhart, Robert, Price, Scott J., Zhu, Y., Wu, Jingshing, Zhu, Wuqiang , Zhu, Wuqiang , Gao, Zhan , Chan, Hsin‐Ju , Osei, Kwame, Rogers, Holden T. , Gearhart, Robert L., Price, Scott J., Brasier, Allan R. , Ge, Ying Ping

Mayo Clinic

No container title available | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8811072/v1 | PMID 41727594 Get It

Abstract Histones variant composition and post-translational modifications (PTMs) of core and linker histones jointly orchestrate chromatin architecture and tissue-specific gene regulation. However, capturing the full complexity of the “histone code” in native human tissues remains challenging. Here we present a human cardiac histone proteoform atlas—comprising intact histone variants with combinatorial PTMs—enabled by a streamlined top‑down proteomics workflow. In a single one‑dimensional reversed‑phase liquid chromatography (LC)-mass spectrometry (MS) run, we achieve baseline separation of all four core histone families (H2A, H2B, H3, and H4) together with the linker histone H1 directly from human myocardium. Notably, this intact-protein analysis preserves the connectivity of co-occurring PTMs to individual histone molecules to reveal the combinatorial histone code, enabling proteoform‑level quantification of histone‑variant composition and PTM stoichiometry at the chromatographic scale. Targeted MS/MS directly resolves co-occurring PTM combinations and distinguishes highly homologous histone isoforms. Using this approach, we assemble the first comprehensive cardiac histone proteoform atlas and uncover previously unobserved histone proteoforms. More broadly, this top-down proteomics workflow provides a robust framework for proteoform-resolved analysis of histone variants and PTMs in complex biological systems.
Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus
Gross, Seth, Shaukat, Aasma, Afzali, A, Ahn, Joseph C., Bajaj, Jasmohan S. , Barkin, Jodie A. , Bilal, Mohammad, Chawla, Saurabh , Coelho-Prabhu, Nayantara, Enslin, Sarah , Feld, Andrew, Gagneja, Harish K., Hass, David J., Horst, Sara N., Jones, Patricia D. , Kushnir, Vladimir M., Leggett, Cadman L. , Leung, Galen G., Mascarenhas, M., Parasa, Sravanthi, Parsa, Nasim , Schairer, Jason N., Spiegel, Brennan, Suthrum, Praveen, Thomas, Sapna, Phillips, Meridith E., Coelho–Prabhu, Nayantara , Spiegel, Brennan , Afzali, Anita , Ahn, Joseph , Bilal, Mohammad , Afzali, Anita , Ahn, Joseph C , Coelho-Prabhu, Nayantara , Enslin, Sarah M , Hernandez-Barco, Yasmin G , Horst, Sara , Jacobson, Brian C , Jones, Patricia D , Kaul, Vivek , Leggett, Cadman L , Leung, Galen , Mascarenhas, Miguel , Parasa, Sravanthi , Shah, Eric D , Simonetto, Douglas A , Stidham, Ryan W , Suthrum, Praveen , Thomas, Sapna , Phillips, Meridith E , Bilal, Mohammad , Spiegel, Brennan , Shaukat, Aasma , Afzali, Arya , Feld, Andrew D., Hernandez‐Barco, Yasmin G. , Horst, Sara , Kushnir, Vladimir , Parasa, Sravanthi , Schairer, Jason, Shah, Eric D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 1017-1024

10.14309/ajg.0000000000003944 | PMID 41665234 Get It

INTRODUCTION: The American College of Gastroenterology assembled a multidisciplinary task force to evaluate the current state and future direction of artificial intelligence (AI) in gastroenterology, hepatology, and endoscopy leading to the development of consensus-based recommendations for responsible AI integration in clinical practice. METHODS: A total of 32 subject-matter experts and 12 industry partners, representing diverse practice settings and expertise, conducted subgroup literature reviews across 5 key areas (endoscopy, practice management clinical applications, training and education, inflammatory bowel disease and liver disease, ethics and equity). Draft statements were developed and rated on a 5-point Likert scale using a modified Delphi process. A consensus was set at ≥70% combined agreement. Nonconsensus items were revised and revoted electronically. RESULTS: A total of 43 statements, 40 (93%) reached consensus in round 1 and the remaining 3 achieved consensus after round 2. Evidence supports computer-aided detection improving adenoma detection rate and miss rate in controlled studies, with mixed real-world impact and insufficient long-term outcomes (e.g., interval colon cancer rate). Recommendations emphasize thorough validation and reduction of bias by heterogeneous Data sets. Outside endoscopy, ambient AI scribes, natural language processing (NLP)-enabled coding, workflow optimization, and previous authorization support show potential. Training recommendations endorse a structured AI curriculum while preserving independent procedural competence to avoid deskilling. In inflammatory bowel disease and hepatology, AI could help improve diagnostic accuracy, help predict risk of disease progression, and help guide therapy. Equity, governance, and reimbursement statements call for chain-of-custody data protections, specialty-society oversight, and payment models that reward quality and cost reduction. DISCUSSION: This consensus outlines how AI can augment rather than replace clinical expertise while promoting safety, transparency, interoperability, and equity. Priorities include pragmatic and prospective trials, multi-institutional data-sharing consortia, bias mitigation, and workforce training to enable trustworthy and clinically impactful AI adoption in gastroenterology, liver, and endoscopy care.
Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspective
Kalil, Andre C, Yaghoubi, Mohsen , Ahuja, Neera , Kadambi, Ananth , Oppelt, Thomas , Kuritzkes, Daniel R. , Oppelt, Thomas F , Kalil, André C. , Yaghoubi, Mohsen, Rivera, Christina G.

Mayo Clinic

American Journal of Health-System Pharmacy | February 10, 2026 | Volume: 83 | Issue: Supplement_3 | Pages: S2952-S2961

10.1093/ajhp/zxag038 | PMID 41671406 Get It

Abstract Purpose SARS-CoV-2 infection continues to impact global health, particularly among high-risk vulnerable individuals. With the loss of federal funding for SARS-CoV-2 management, hospitals will need to budget appropriately for antivirals like remdesivir, which has demonstrated effectiveness in reducing mortality. We evaluated the economic impact realized by hospitals for patients hospitalized for SARS-CoV-2 infection and initiated on remdesivir therapy. Methods We conducted a retrospective analysis using data compiled in the Premier Healthcare Database from January 2023 to February 2024. Propensity score matching was used to compare remdesivir-treated (RDV) and untreated (No RDV) groups. The mortality rate, hazard ratios associated with remdesivir use, and hospitalization costs were assessed overall and among the elderly (age ≥65 years). We also conducted a cost-effectiveness analysis to assess the economic value of remdesivir treatment. Results Among 25,498 hospitalized patients, the mortality rate in the RDV group was lower than in the No RDV group (6.2% versus 8.1%), with a greater reduction in the elderly (6.9% versus 9.0%). Remdesivir significantly reduced mortality risk by approximately 25% overall and among the elderly. Each life saved was realized at a minimal increase in average hospitalization costs ($18,329 in the RDV group versus $14,845 in the No RDV group). Remdesivir was a cost-effective treatment option at a willingness-to-pay threshold of $25,000 overall and among the elderly. Conclusions Our evaluation provides contemporaneous evidence of benefits and costs associated with management of individuals hospitalized for SARS-CoV-2 infection. Initiation of remdesivir was associated with minimal incremental hospitalization costs for lives saved as compared to not initiating remdesivir. Hospital pharmacy leadership can utilize this real-world evidence to appropriately budget for remdesivir treatment.
Familial History of Aortic Disease Does Not Affect Outcomes of Fenestrated-Branched Endovascular Aortic Repair in Patients With Complex Aortic Aneurysms
Baghbani, Aidin , Sulzer, Titia A.L. , Mesnard, Thomas, Mendes, Bernardo C., Saqib, Naveed, Huang, Ying, Oderich, Gustavo S., Baghbani‐Oskouei, Aidin , Sulzer, Titia A L , Tenorio, Emanuel R , Huang, Ying , Oderich, Gustavo S , Savadi, Safa , Tenorio, Emanuel R. , Mésnard, Thomas , Vacirca, Andrea , Mendes, Bernardo C. , Maximus, Steven , Oderich, Gustavo S.

Mayo Clinic

Journal of Endovascular Therapy | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15266028261417156 | PMID 41664301 Get It

Purpose: Familial history of aortic disease has been associated with increased risk of aneurysm-related complications after standard endovascular aortic repair. The aim of this study was to evaluate outcomes of fenestrated-branched endovascular aortic repair (FB-EVAR) for complex aortic aneurysms in patients with or without familial aortic aneurysms (FAAs). Materials and Methods: We reviewed the clinical data of consecutive patients enrolled in a prospective non-randomized study to investigate outcomes after FB-EVAR for treatment of complex aortic aneurysms between 2013 and 2022. Familial aortic aneurysm was defined as occurrence of an aortic aneurysm or dissections in a first- or second-degree relative and compared with patients with sporadic aortic aneurysms (SAAs). Endpoints included procedural metrics, 30-day mortality and major adverse events (MAEs), mid-term patient survival, freedom from reintervention and endoleak, and aneurysm sac shrinkage. Results: There were 499 patients treated with FB-EVAR (70% males, mean age was 74±7.7 years) including 66 (13%) patients with FAAs and 434 (87%) with SAAs. Both groups had similar demographics, clinical characteristics, aneurysm extent, and prior history of aortic dissection or aortic repair. Patients with FAAs had longer fluoroscopy time (82 vs 71 minutes) and radiation exposure (1856 vs 1213 mGy; each p<0.05), with no difference in technical success (FAA, 94% vs SAA, 97%; p=0.51). There was no difference in 30-day mortality (1.5% vs 0.9%; p=1.00) and MAEs (23% vs 18%; p=0.44) among patients with FAA and SAA, respectively. Median follow-up was 28 months. At 3 years, patient survival, freedom from secondary interventions, and cumulative incidence of sac shrinkage were 76±2.5%, 74±2.5%, and 32±2.6% for all patients, respectively, with no difference between FAA and SAA groups. Conclusion: Fenestrated-branched endovascular aortic repair was performed with high technical success, low mortality, and low incidence of MAEs regardless of the presence of FAA. There was no difference in mid-term patient survival, secondary interventions, and sac changes among patients with or without family history of aortic disease. Clinical Impact This study demonstrates that fenestrated-branched endovascular aortic repair (FB-EVAR) can be performed with high technical success and comparable early and mid-term outcomes in patients with or without a familial history of aortic aneurysm, after exclusion of genetically triggered aortic diseases. These findings challenge the assumption that family history alone should preclude complex endovascular repair. Clinically, this supports broader use of FB-EVAR in carefully selected patients with familial aortic disease, emphasizing anatomical suitability rather than pedigree alone. The innovation lies in validating FB-EVAR as a safe alternative to open repair for this understudied population, informing patient selection, counseling, and surveillance strategies.
The influence of midlife morbidity clusters on dementia risk: The ARIC study
Kinyanjui, Elise, Groechel, Renee C., Morrill, Valerie, Walker, Keenan A., Kucharska‐Newton, Anna M., Mosley, Thomas H., Koton, Silvia , Knopman, David S., Weiss, Jordan, Gottesman, Rebecca F., Egle, Marco , Weiss, Jordan , Groechel, Renée C. , Morrill, Valerie, Walker, Keenan A. , Mosley, Thomas H. , Knopman, David S. , Weiss, Jordan, Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia | February 10, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71110 | PMID 41663335 Get It

Abstract INTRODUCTION Understanding comorbidities’ combined impacts on dementia risk may offer a more comprehensive understanding of individuals’ risk. Using machine‐learning, we grouped individuals with similar midlife risk profiles into clusters and explored associations with dementia risk. METHODS Participants without dementia at baseline (1987–1989) from the prospective Atherosclerosis Risk in Communities (ARIC) study were included (ages 45–64 years; N = 15,250). Using unsupervised hierarchical cluster analysis, nine clusters were created and defined based on 14 midlife morbidities. The associations with incident dementia ( N = 3272 cases, median follow‐up 25 years) and deaths ( N = 9099) were evaluated using time‐to‐event regression models. RESULTS Compared with the healthiest cluster (Cluster 1), Clusters 2 (smoking) (hazard ratio [HR](95% confidence interval [CI]) = 1.62 (1.08, 2.43)), 5 (obesity, diabetes, hypertension, and hypertriglyceridemia) (HR(95%CI) = 1.91 (1.35,2.70)), and 7/8 (atrial fibrillation/heart failure) (HR(95%CI) = 2.69 (1.59,4.57)) were associated with dementia. Accounting for competing risk of death in the Fine‐Gray subdistribution model negated the cluster‐dementia association. DISCUSSION Midlife morbidity clusters are important for dementia and mortality risk.
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Jegede, Opeyemi A. , Wang, Victoria, Ansell, Stephen M., Kostakoglu, Lale, Steidl, Christian , Natkunam, Yasodha , Scott, David W., Ambinder, Richard F, David, Kevin A. , Advani, Ranjana H, Bartlett, Nancy L., Thomas, Sachdev , Cohen, Jonathon B. , Goyal, Gaurav, Mehta-Shah, Neha, Amengual, Jennifer E. , Forlenza, Christopher Jon, Cole, Peter D. , Duan, Fenghai , Kelly, Kara M, Advani, Ranjana H. , Scott, David W. , Kostakoglu, Lale , Diefenbach, Catherine S , Jagede, Opeyemi A. , Kostakoglu, Lale , Steidl, Christian , Natkunam, Yasodha , Scott, David W , Ambinder, Richard F , David, Kevin , Bartlett, Nancy L , Thomas, Sachdev P , Cohen, Jonathon B , Goyal, Guarav , Mehta-Shah, Neha , Amengual, Jennifer E , Cole, Peter D , Advani, Ranjana H , Diefenbach, Catherine , Wang, Victoria , Ansell, Stephen M. , Ambinder, Richard F. , Bartlett, Nancy L. , Robertson, Michael J. , Ibrahimi, Sami , Goyal, Gaurav , Mehta–Shah, Neha , Forlenza, Christopher J. , Kelly, Kara M , Kahl, Brad S.

Mayo Clinic

Blood | February 9, 2026 | Volume: 147 | Issue: 18 | Pages: 2041-2052

10.1182/blood.2025029546 | PMID 41662628 Get It

Abstract The phase 1/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) in relapsed/refractory classic Hodgkin lymphoma. A total of 147 patients aged ≥12 years were randomized between BV/Nivo and BV/Ipi/Nivo; 132 patients were included in the primary efficacy analysis. The complete response (CR) rate, was 64.7% (52.2, 75.9) for BV/Nivo and 70.3% (57.6, 81.1) for BV/Ipi/Nivo (1-sided P = .29). The median survival follow-up was 38.0 months (interquartile range, 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the 2 arms (hazard ratio [HR], 0.78, confidence interval [CI], 0.39-1.57; 1-sided P = .24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, were similar between both arms (38.5% BV/Nivo and 39.3% BV/Ipi/Nivo); there was a higher frequency of grade 3 rash with BV/Ipi/Nivo (24.6%) compared with BV/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned before hoc comparison; 58 patients received SCT, and 36-month PFS (from SCT) was &gt;90% for both arms. Sixty-six patients were progression free after the first scan and did not undergo SCT. The 36-month PFS was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared with 45.8% (26.3, 63.4) for BV/Nivo (HR, 0.45; CI, 0.19-1.08; 1-sided P = .03). The study did not meet its primary end point of superior CR rate for the triplet, but it supports the use of checkpoint antibody-drug conjugate induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT with the triplet of BV/Ipi/Nivo. This trial was registered at www.clinicaltrials.gov as NCT01896999.
D-Dimer Reporting and Harmonization: Analysis of College of American Pathologists D-Dimer Proficiency Testing Program
Salazar, Eric, Smock, Kristi J. , Cazzolli, Taryn E, Dlott, Jeffrey S., Lickteig, Nathan, Long, Thomas A., Mulvey, J. Justin , Gil, Morayma Reyes, Rollins-Raval, Marian, Walker, Chance Avery, Zantek, Nicole D. , Goodwin, AJ, Zantek, Nicole D , Gil, Morayma Reyes , Rollins‐Raval, Marian A. , Teruya, Jun , Volod, Oksana , Walker, Chance, Wool, Geoffrey D.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | February 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2803-3165 | PMID 41651008 Get It

Abstract Measurement of D-dimer, a fibrin degradation product, is crucial for diagnosing thrombotic and fibrinolytic conditions. Despite its expanding utility, D-dimer testing faces challenges due to varying assay methodologies and nonstandardized reporting. To understand D-dimer reporting practices, the College of American Pathologists Hemostasis and Thrombosis Committee analyzed proficiency testing data from D-dimer surveys conducted between 2020 and 2023 across multiple laboratories. The data demonstrate that laboratories commonly report units that differ from the assay package insert when reporting their proficiency testing results. We sought to assess variability in reporting practices and opportunities for improvement in D-dimer reporting amongst participants. To accomplish this, we harmonized all D-dimer results to ng/mL fibrinogen equivalent units from one distributed sample and assessed distinct populations of entries per instrument/reagent combination. Notable trends emerged from this analysis. Data from laboratories using the same instrument/reagent combinations clustered around different means, suggesting issues with unit reporting and/or conversion. Entries reported in mg/L or ug/mL D-dimer units commonly exhibited significant deviations from the dominant population. For one instrument/reagent combination, most reported values differed by approximately twice the certificate of analysis value. This analysis highlights potential issues with D-dimer reporting in proficiency testing. Whether these issues translate into issues with clinical D-dimer reporting requires further study.
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Voermans, Nicol C, Statland, J., Hayward, Lawrence J. , Rosenbohm, Angela , Munain, Adolfo López de, Sacconi, Sabrina, Leung, D., Vissing, John, Schoser, Benedikt, Lochmüller, H., Bugiardini, E., Wang, Leo H. , Maggi, Lorenzo, Ragole, Thomas , Pestronk, Alan , Hamel, Johanna , Goyal, Namita A, Korngut, Lawrence, Naddaf, Elie, Harper, A., Shieh, Perry, Kornblum, Cornelia , Sansone, Valeria, Genge, A., Tasca, G., Jiang, John , Jouvin, Marie‐Hélène , Tawil, Rabi , Investigators, on behalf of the REACH, Leung, Doris G , Muelas, Nuria , Wang, Leo H , Pestronk, Alan , Goyal, Namita A , Harper, Amy , Tasca, Giorgio , Tawil, Rabi , Voermans, Nicol Cornelia , Statland, Jeffrey M., Munaín, Adolfo López de , Sacconi, Sabrina , Badrising, Umesh A. , Vissing, John , Schoser, Benedikt , Bugiardini, Enrico , Maggi, Lorenzo , Korngut, Lawrence , Naddaf, Elie , Shieh, Perry B. , Sansone, Valeria , Genge, Angela

Mayo Clinic

Journal of Neuromuscular Diseases | February 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/22143602261419558 | PMID 41649965 Get It

Background: Losmapimod is an orally administered small molecule and selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor able to reduce aberrant expression of DUX4 in vitro and thereby potentially slowing disease progression in patients with facioscapulohumeral muscular dystrophy (FSHD). Objective: This global, randomized, placebo-controlled, double-blind phase 3 study in patients with FSHD1 and FSHD2 examined the efficacy and safety of losmapimod over a 48-week treatment period compared to placebo (NCT05397470, EUDRACT 2022-000389-16). Methods: The primary endpoint was change in quantification of reachable workspace (RWS) expressed as relative surface area (RSA). Other endpoints included measures of muscle composition (fat content and lean muscle) using magnetic resonance imaging (MRI), muscle strength using quantitative dynamometry, and quality of life measures. Results: 130 participants received losmapimod and 130 participants received placebo, with 252 participants completing the 48-week treatment period. There were no statistically significant differences between groups in change in RSA and all secondary efficacy endpoints from baseline to Week 48. Losmapimod treatment was well-tolerated, and most adverse events were mild. Conclusions: Losmapimod was generally well tolerated with a favorable safety profile at a dose of 15 mg twice daily. Although none of the efficacy endpoints were met, study design and data from the study may inform future studies of FSHD therapies.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.